期刊
FUTURE ONCOLOGY
卷 10, 期 14, 页码 2293-2301出版社
FUTURE MEDICINE LTD
DOI: 10.2217/fon.14.110
关键词
breast cancer; estrogen receptor; progesterone receptor
类别
资金
- Ministry of Higher Education, Malaysia [UM.C/HlR/MOHE/06]
Breast cancer is the most common cancer in women worldwide. The majority of breast cancers show overexpression of estrogen receptors (ERs) and progesterone receptors (PRs). The development of drugs to target these hormone receptors, such as tamoxifen, has brought about significant improvement in survival for women with hormone receptor-positive breast cancers. Since information about ER and PR is vital for patient management, quality assurance is important to ensure accurate testing. In recent guidelines, the recommended definition of ER and PR positivity is 1% or more of cells that stain positive. Semiquantitative assessment of ER and PR is important for prognosis and, hence, management. Even with the development of genomic tests, hormone receptor status remains the most significant predictive and prognostic biomarker.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据